Target intelligence / Profile preview

Pancreatic lipase (PNLIP) (PNLIP)

Target
PNLIP
Molecular classification
Enzyme, Serine hydrolase, Alpha/beta hydrolase fold
01

Overview

Pancreatic lipase, also known as human pancreatic lipase (PNLIP), is the primary enzyme responsible for digesting dietary triglycerides in the small intestine, hydrolyzing them into monoglycerides and free fatty acids for absorption.[1][3][7] It belongs to the alpha/beta hydrolase superfamily and employs a catalytic triad of serine, histidine, and aspartic acid to perform interfacial activation at the oil-water boundary, requiring colipase as a cofactor to function optimally amid bile salts.[1][2][3] Secreted by the pancreas into the duodenum, it processes 50-70% of ingested fats, playing a central role in lipid metabolism and energy homeostasis.[5][7] Dysregulation or deficiency leads to fat malabsorption in pancreatic insufficiency, while serum elevations serve as a key biomarker for acute pancreatitis.[1][3] Therapeutically, it is targeted via replacement therapies like pancrelipase in conditions such as cystic fibrosis or chronic pancreatitis, though high doses pose risks like fibrotic bowel changes.[1] As part of broader lipase families, it exemplifies serine hydrolases critical for digestion across organisms, with industrial microbial analogs used in biocatalysis.[1][2]

Other names
human pancreatic lipase (HPL)pancreatic triacylglycerol lipasePNLIPPL
02

Mechanism of action

Inhibition of interfacial activation at oil-water interface (for some microbial lipases used industrially); Catalytic triad (Ser-His-Asp) hydrolysis of triglycerides requiring colipase cofactor in bile salts; Exogenous lipase supplementation hydrolyzes undigested dietary triglycerides in pancreatic insufficiency

03

Biological functions

Hydrolysis of triglycerides to fatty acids and monoglyceridesDietary lipid digestionLipid metabolismFat absorption in small intestine
04

Disease associations

Pancreatitis (elevated serum levels diagnostic)Pancreatic insufficiencyCholesteryl ester storage disease (related lysosomal lipase)Wolman disease (related lysosomal lipase)Lipoprotein lipase deficiency (related)
05

Safety considerations

Hyperlipasemia from pancreatic enzyme replacement therapy (PERT)Risk of fibrosing colonopathy with high-dose PERTPotential for viral transmission in non-purified porcine-derived lipases (mitigated in modern formulations)
06

Interacting drugs

Liprotamase (Sollpura; pancreatic enzyme replacement containing lipase)

1 more in the full profile.

07

Biomarkers

Serum lipase levels (elevated in acute pancreatitis; diagnostic blood test)

Beyond the preview

Go deeper on Pancreatic lipase (PNLIP) (PNLIP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pancreatic lipase (PNLIP) (PNLIP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call